Supporting our findings, Marabelle et al. recently reported that the addition of CpG to low doses of anti-CTLA-4 and anti-OX40 (two antibodies directed against surface markers of tumor-specific Treg cells) injected locally in a peripheral tumor site in the rat expanded anti-tumor responses to distant tumor sites including the brain [40]. Here, TNFRSF4 is linked to neoplasm.